Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
120.50    2.50 (2.12%)
Bid:
118.00
Ask:
123.00
Spread: 5.00 (4.237%)
Market Cap: £72.50m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

5 Apr 2017 07:00

RNS Number : 5897B
Intercede Group PLC
05 April 2017
 

 

5 April 2017

INTERCEDE GROUP plc

("Intercede", or the "Group")

Trading Update

 

Intercede announced on 3 March 2017 that the revenue outturn for the financial year ending 31 March 2017 would be approximately £8.0m, with a further £2.0m of new orders in the near term pipeline. The Group today confirms that three of these contract orders were received by the end of the trading period. Subject to the completion of the year end audit, revenues for the year ending 31 March 2017 are expected to be between £8.2 - 8.4m.

The new orders include two customer wins that relate to the deployment of MyID within a US Government Agency and a US Healthcare group. Intercede continues to work diligently to bring the remainder of the near term pipeline into reported revenue. It is confident that this will occur within the first half of the year to 31 March 2018.

The Group is also pleased to report that gross cash balances for the year are £6.9m. This compares to the £6.0m forecast which it highlighted in the earlier statement.

Further detail will be provided within Intercede's final results for the year ending 31 March 2017 which are expected to be published during the week commencing 5 June 2017.

Commenting on the financial close to the year, Richard Parris, Chairman and CEO of Intercede, said;

"After the uncertainty created by the initial phase of the new US Administration, we are pleased that business appears to be returning to normal. Importantly, there is progress in securing the remainder of our near term pipeline and encouraging signs of demand within our core markets. Momentum is building and we view the future with considerable confidence".

Contact

Intercede Group plc

Tel: +44 (0) 1455 558 111

Richard Parris

Chairman & Chief Executive

Andrew Walker

Finance Director

finnCap

Tel: +44 (0) 20 7220 0500

Stuart Andrews

Corporate Finance

Simon Hicks

Corporate Finance

Capital Access Group

Tel: +44 (0) 20 3763 3400

Scott Fulton

Media

Ed Welsby

Investors

About Intercede

Intercede is a software and service company specializing in identity, credential management and secure mobility. Its solutions create a foundation of trust between connected people, devices and apps and combine expertise with innovation to provide world-class cybersecurity. Intercede has been delivering solutions to high profile customers, from the US and UK governments to some of the world's largest corporations, telecommunications providers and information technology firms, for over 20 years. Intercede's product portfolio includes MyID, an identity and credential management system that assigns trusted digital identities to employees citizens and machines. In 2015, Intercede launched MyTAM, enabling trusted applications to be loaded into a mobile device's Trusted Execution Environment (TEE), providing hardware-level security for Android apps. In 2016, Intercede launched RapID, a secure, easy to implement authentication service for mobile apps and cloud services to completely eliminate the need for passwords.

For more information visit: www.intercede.com

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSSFMLFWSELL
Date   Source Headline
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.